Nilo Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $101M
Overview
Developing novel small molecule drugs targeting undruggable pathways in oncology.
Oncology
Technology Platform
A proprietary drug discovery platform targeting historically undruggable oncology targets through integrated computational and medicinal chemistry.
Funding History
1Total raised:$101M
Venture$101M
Opportunities
Potential for high-value partnerships or acquisition if its platform successfully generates validated clinical candidates against novel targets.
Risk Factors
High technical risk of failing to translate platform hits into safe, effective drugs, coupled with the significant capital and time required to reach clinical proof-of-concept.
Competitive Landscape
Faces intense competition from numerous biopharma companies also pursuing novel small molecules in oncology, particularly in the 'undruggable' target space.